- Home
- NDLS vs AKTX Comparison
NDLS vs AKTX Comparison
Compare NDLS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- AKTX
- Stock Information
- Founded
- NDLS 1995
- AKTX N/A
- Country
- NDLS United States
- AKTX United States
- Employees
- NDLS N/A
- AKTX N/A
- Industry
- NDLS Restaurants
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- AKTX Health Care
- Exchange
- NDLS Nasdaq
- AKTX Nasdaq
- Market Cap
- NDLS 32.9M
- AKTX 35.7M
- IPO Year
- NDLS 2013
- AKTX N/A
- Fundamental
- Price
- NDLS $0.87
- AKTX $1.11
- Analyst Decision
- NDLS Strong Buy
- AKTX Strong Buy
- Analyst Count
- NDLS 2
- AKTX 1
- Target Price
- NDLS $3.00
- AKTX $5.00
- AVG Volume (30 Days)
- NDLS 234.3K
- AKTX 17.3K
- Earning Date
- NDLS 08-06-2025
- AKTX 08-18-2025
- Dividend Yield
- NDLS N/A
- AKTX N/A
- EPS Growth
- NDLS N/A
- AKTX N/A
- EPS
- NDLS N/A
- AKTX N/A
- Revenue
- NDLS $495,670,000.00
- AKTX N/A
- Revenue This Year
- NDLS $5.37
- AKTX N/A
- Revenue Next Year
- NDLS $0.68
- AKTX N/A
- P/E Ratio
- NDLS N/A
- AKTX N/A
- Revenue Growth
- NDLS N/A
- AKTX N/A
- 52 Week Low
- NDLS $0.55
- AKTX $0.85
- 52 Week High
- NDLS $1.83
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- NDLS 59.19
- AKTX 43.71
- Support Level
- NDLS $0.80
- AKTX $1.08
- Resistance Level
- NDLS $0.92
- AKTX $1.15
- Average True Range (ATR)
- NDLS 0.07
- AKTX 0.03
- MACD
- NDLS 0.01
- AKTX 0.00
- Stochastic Oscillator
- NDLS 88.89
- AKTX 39.12
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.